

Iowa Department of Human Services

Request for Prior Authorization IDIOPATHIC PULMONARY FIBROSIS

FAX Completed Form To 1 (800) 574-2515

> Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address	Fax			
Pharmacy name	Address	Phone		
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax NDC			

Prior authorization is required for pirfenidone (Esbriet[®]) and nintedanib (Ofev[®]). Dosing outside of the FDA approved dosing will not be considered. Concomitant use of pirfenidone and nintedanib will not be considered. Payment will be considered for patients when the following criteria are met:

- 1) Patient is 40 years of age or older; and
- 2) Is prescribed by a pulmonologist; and
- 3) Patient has a diagnosis of idiopathic pulmonary fibrosis as confirmed by one of the following (attach documentation):
 - Findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP); or
 - A surgical lung biopsy demonstrating usual interstitial pneumonia (UIP); and
- 4) Prescriber has excluded other known causes of interstitial lung disease (ILD) such as domestic and occupational environmental exposures, connective tissue disease, and drug toxicity; and
- 5) Patient has documentation of pulmonary function tests within the prior 60 days with a forced vital capacity (FVC) ≥ 50% predicted; and
- 6) Patient has a carbon monoxide diffusion capacity (%DLco) of \geq 30% predicted; and
- 7) Patient does not have hepatic impairment as defined below:
 - Nintedanib Patient does not have moderate or severe hepatic impairment (Child-Pugh B or C) or
 - Pifenidone Patient does not have severe hepatic impairment (Child-Pugh C); and
- 8) Patient does not have renal impairment as defined below:
 - Nintedanib Patient does not have severe renal impairment (CrCl < 30 mL/min) or end-stage renal disease or
 - Pifenidone Patient does not have end-stage renal disease requiring dialysis; and
- 9) Patient is a nonsmoker or has been abstinent from smoking for at least six weeks.

If criteria for coverage are met, initial authorizations will be given for 6 months. Additional authorizations will be considered at 6 month intervals when the following criteria are met:

- Adherence to pirfenidone (Esbriet[®]) and nintedanib (Ofev[®]) is confirmed; and
- Patient is tolerating treatment defined as improvement or maintenance of disease (<10% decline in percent predicted FVC or < 200 mL decrease in FVC); and
- Documentation is provided that the patient has remained tobacco-free; and
- ALT, AST, and bilirubin are assessed periodically during therapy.

Iowa Department of Human Services

Request for Prior Authorization IDIOPATHIC PULMONARY FIBROSIS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Non-Preferred					
Esbriet Ofev					
trength Dosage Instructions		Quantity	Days Supply		
Is Prescriber a Pulmonologist?] No				
Attach results of high-resolution computed tomogra interstitial pneumonia (UIP).	ohy (HRCT) or surgic	al lung biops	sy indicating usual		
Has prescriber excluded other known causes of inter	rstitial lung disease (ILD)?	Yes 🗌 No		
Patient has pulmonary function test within the prior 60 days documenting a forced vital capacity (FVC) ≥ 50% predicted:					
Patient has a carbon monoxide diffusion capacity (%	DLco) of ≥ 30% pred	icted?	Yes (attach results)] No	
Does patient have moderate to severe hepatic impairment? Yes, Child Pugh B Yes, Child Pugh C No					
Does patient have moderate to severe renal impairme	ent or end-stage rena	al disease?	Yes] No	
CrCl: Date obtained:	Is patient on o	dialysis?	Yes 🗌 No		
Patient is a nonsmoker or has been abstinent from smoking for at least 6 weeks?					
Renewal Requests:					
Patient is adherent to therapy:					
Patient has remained tobacco-free: Yes No					
Patient is tolerating treatment defined as improvement or maintenance of disease (attach results):					
< 10% decline in percent predicted FVC or					
< 200 mL decrease in FVC					
ALT, AST, and bilirubin are being assessed periodica	ally: 🗌 Yes 🔲 No	Most recent	date obtained:		
Other medical conditions to consider:					
Attach lab results and other documentation as necessary.					
Prescriber signature (Must match prescriber listed above.)		Date of subm	ission		

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.